Project Medtech artwork

Episode 92 | Nick Accordino and Will Braeutigam: Deloitte | Taking your Medtech Company Public: SPACs vs. IPOs

Project Medtech

English - May 09, 2022 05:00 - 1 hour - 63.8 MB
Life Sciences Science Homepage Download Google Podcasts Overcast Castro Pocket Casts RSS feed

Previous Episode: Episode 91 | Ashley Mooneyham: President and Director of Grants at Superior Medical Experts | The Wonderful Thing about Grants Is Grants are Wonderful Things

Next Episode: Episode 93 | Danielle Bodicoat | The Scientific Art of Biostats: Clinical Strategy, Sample Size Calculation, Clinical Trial Design, and CEP/CERs

In this episode, Nick Accordino and Will Braeutigam from Deloitte and Duane Mancini discuss discuss SPACs, what are SPACs, why would a company want to go public, the differences in going public through an IPO vs. SPAC, strategic acquisition vs. going public, the myths of going public via a SPAC, preparing your company to go public, and so much more.
Nick Accordino LinkedIn
Will Braeutigam LinkedIn
Deloitte Website
Project Medtech Website
Duane Mancini LinkedIn
Project Medtech LinkedIn